Mechanisms determining prices of products on the pharmaceutical market
DOI:
https://doi.org/10.14595/PES/02/023Abstract
The pharmaceutical market is characterized by the existence of state regulations restricting his freedom to market and is one of the fastest growing sectors of the economy all over the world. Factors that have a real impact on determining the price of drugs can be grouped into three categories: medical factors, economic factors, political and environmental factors. In the group of medical factors can be distinguished patent protection, the cost of producing the drug and the value of the drug. To economic factors, taking into account the aspect of market competitiveness of companies, include: the size of the producer, nature of the company - whether it is a research unit of the pharmaceutical company, return on investment – effectiveness of use of expenditure with the aim of achieving a profit (return on investment, ROI), profitability entity. The remaining group of factors (environmental, and political) relate mainly to national regulations. They are connected with among others the registration system of marketing authorization, whether a reimbursement system that determines whether and how drugs are financed from public funds. Membership in the European Union forces on all Member States to make reimbursement decisions by the so-called Transparency Directive. It is connected with the obligation to justify decisions, and calling upon objective reasons. Medical Technology Assessment Agency formulating recommendations take into account factors i.e. a therapeutic, benefits for the patients, cost-effectiveness, impact on the budget.
References
CHOMONT K., GRZEBIELUCH J., 2012. Analiza procesów kształtowania cen leków na rynku farmaceutycznym w Polsce. Część 2, Pielęgniarstwo i Zdrowie Publiczne, Vol. 2, Nr 1, s. 49-55.
CZECH M., 2010. Farmakoekonomika i ocena technologii medycznych w gospodarowaniu lekami w Polsce. Diagnoza i koncepcje zmian, Wolters Kluwer business, Warszawa.
EFPIA, 2014. The Pharmaceutical Industry in Figures, http://www.efpia.eu/uploads/Figures_2014_Final.pdf.
GOLINOWSKA S., 2008. RAPORT. Finansowanie ochrony zdrowia w Polsce, Zielona Księga II, Warszawa, http://www.sluzbazdrowia.com.pl/pdf/ZielonaKsiegaII.pdf.
HAWKINS L., 2011, WHO/HAI Project on Medicine Prices and Availability Review Series on Pharmaceutical Pricing Policies and Interventions, World Health Organization and Health Action International.
LIS J., SKRZEKOWSKA-BARAN I., WENDYKOWSKA K., 2009. Ustalanie cen produktów leczniczych przez producentów, w: Łanda K., (red.), Pricing. Ceny leków refundowanych, negocjacje i podział ryzyka, CEESTAHC, Kraków/Warszawa.
LIS J., WENDYKOWSKA K., ADAMSKI J., BONDARYK K., BUDASZ-ŚWIDERSKA M., OFIERSKA-SUJKOWSKA G., ŁANDA K., SKRZEKOWSKA-BARAN I., 2009. Mechanizmy regulazji i kontroli cen leków, w: Łanda K., (red.), Pricing. Ceny leków refundowanych, negocjacje i podział ryzyka, CEESTAHC, Kraków/Warszawa.
MICHALIK M., MRUK H., PILARCZYK B., 2011. Marketing strategiczny na rynku farmaceutycznym, Wolters Kluwer Polska, Warszawa.
OECD, 2011. Pharmaceutical expenditure, w: Health at a Glance 2011: OECD Indicators, OECD Publishing. http://dx.doi.org/10.1787/health_glance-2011-en.
PAIZ, 2013. Sektor farmaceutyczny i biotechnologiczny w Polsce, Warszawa.
Pharma Expert, 2008. Raport, http://www.pharmaexpert.pl/media-files/PharmaExpert_podsumowuje_rynek_famaceutyczny_za_padziernik_2008_1.pdf.
SORENSON C., KANAVOS P., DRUMMOND M., 2008, Ensuring value for money in health care: the role of HTA in the Europe Union, WHO.
ZAPRUTKO T., NOWAKOWSKA E., RATAJCZYK B., KOLIGAT D., KUS K., PACZKOWSKA A., 2012. Ceny leków oraz znaczenie importu równoległego dla rynków farmaceutycznych w 3 krajach Unii Europejskiej, Nowiny Lekarskie, Vol. 81, Nr 2, s. 136-144.
Downloads
Published
Issue
Section
License
Articles in Progress in Economic Sciences in printed and online versions are published on the basis of Open Access principles under CC - Creative Commons Attribution. Authors are free to use texts published in the journal.